Merck & Co. (MRK) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA (pembrolizumab), the company�s anti-PD-1 therapy, for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. Data supporting the CHMP opinion were based on two studies, KEYNOTE-010, which assessed overall survival (OS) and KEYNOTE-001, which assessed overall response rates (ORR).